Fisher Funds Management LTD Invests $709,000 in Solventum Co. (NYSE:SOLV)

Fisher Funds Management LTD bought a new stake in shares of Solventum Co. (NYSE:SOLV) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 10,734 shares of the company’s stock, valued at approximately $709,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in SOLV. Worldquant Millennium Advisors LLC boosted its holdings in Solventum by 373.6% during the third quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock valued at $3,323,000 after purchasing an additional 37,600 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in Solventum by 24.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock valued at $3,103,000 after buying an additional 9,333 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Solventum by 37.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock valued at $8,217,000 after buying an additional 32,051 shares in the last quarter. State Street Corp grew its position in Solventum by 3.1% in the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after acquiring an additional 185,938 shares during the period. Finally, Forsta AP Fonden acquired a new position in Solventum during the fourth quarter worth $1,876,000.

Solventum Price Performance

Shares of SOLV stock opened at $73.08 on Monday. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The firm’s 50 day moving average is $71.14 and its 200-day moving average is $69.24.

Analyst Ratings Changes

Several equities research analysts have recently commented on SOLV shares. Morgan Stanley boosted their target price on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Piper Sandler upped their price objective on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Finally, Mizuho started coverage on shares of Solventum in a report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective for the company. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, Solventum presently has a consensus rating of “Hold” and an average target price of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.